| Adverse event | Adalimumab (N = 311) n (%) |
| Nasopharyngitis | 80 (25.7) |
| Upper respiratory tract infection | 53 (17.0) |
| Headache | 48 (15.4) |
| Arthralgia | 33 (10.6) |
| Sinusitis | 30 (9.6) |
| Fatigue | 25 (8.0) |
| Diarrhoea | 30 (9.6) |
| Nausea | 27 (8.7) |
| Influenza | 23 (7.4) |
| Cough | 26 (8.4) |
| Back pain | 23 (7.4) |
| Hypertension | 23 (7.4) |
| Pharyngolaryngeal pain | 22 (7.1) |
| Bronchitis | 20 (6.4) |
| Viral infection | 19 (6.1) |
| Injection-site reaction | 15 (4.8) |
| Pharyngitis | 19 (6.1) |
| Rash | 17 (5.5) |